Erector Spinae Plane Blocks for Pain Control After Total Laparoscopic Hysterectomy
Effects of Erector Spinae Plane Block and Deep Erector Spinae Plane Block on Postoperative Pain Management in Total Laparoscopic Hysterectomy
This study will compare two nerve block techniques for pain relief after total laparoscopic hysterectomy, a minimally invasive operation to remove the uterus. Both techniques involve injecting a local anesthetic near muscles of the lower back, but the injections are given at different depths.
Women aged 18 to 65 years who are scheduled for this surgery will be randomly assigned to one of three groups: erector spinae plane block, deep erector spinae plane block, or no nerve block. The nerve blocks will be performed on both sides of the lower back after surgery. All participants will receive standard pain medication.
The main aim is to compare pain scores one hour after surgery. The study will also assess pain during the first 24 hours, opioid pain medication use, the time until additional pain relief is needed, nausea and vomiting, time to hospital discharge, patient satisfaction, and quality of recovery.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This single-center, prospective, randomized controlled study will compare ultrasound-guided bilateral erector spinae plane block and deep erector spinae plane block with a control group receiving no block in women undergoing total laparoscopic hysterectomy under general anesthesia.
Participants will be allocated to three groups using computer-generated randomization. Blocks will be performed postoperatively in the recovery unit at the L1 vertebral level. In the erector spinae plane block group, the injection will be administered between the erector spinae muscle and the transverse process. In the deep erector spinae plane block group, the injection will be administered deep to the transverse process, in the plane between the erector spinae and psoas muscles. Both block groups will receive 20 mL of 0.25% bupivacaine on each side. The control group will receive no block.
All groups will receive standardized general anesthesia and perioperative multimodal analgesia. Intravenous meperidine at 0.25 mg/kg will be administered as rescue analgesia when the numerical rating scale pain score exceeds 3.
An anesthesiologist blinded to group allocation will assess pain at rest and during movement. Baseline pain scores (0 minutes) will be recorded before block administration. Subsequent pain assessments in the block groups will be timed from completion of bilateral block administration. In the control group, an equivalent reference time will be established in the postoperative recovery unit, and the same assessment schedule will be followed. Postoperative assessments will include pain scores, opioid consumption, rescue analgesic requirements, nausea and vomiting, discharge time, patient satisfaction, and quality of recovery using the Quality of Recovery-15 questionnaire.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Hande Gurbuz, Prof, MD, PhD
- Phone Number: +90 533 651 56 50
- Email: handegrbz@gmail.com
Study Locations
-
-
Bursa
-
Bursa, Bursa, Turkey (Türkiye), 16110
- University of Health Sciences, Bursa City Hospital
-
Contact:
- Hande Gurbuz, Prof, MD, PhD
- Phone Number: +90 533 651 56 50
- Email: handegrbz@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female patients aged 18 to 65 years.
- Scheduled for elective total laparoscopic hysterectomy.
- American Society of Anesthesiologists (ASA) physical status I, II, or III.
- Provision of written informed consent.
Exclusion Criteria:
- ASA physical status IV or higher.
- Inability to cooperate with pain assessment because of cognitive impairment, a psychiatric condition, or inability to understand Turkish.
- Known allergy to local anesthetics or opioids.
- Body mass index greater than 35 kg/m².
- Infection at the planned injection site.
- Neurological deficits.
- Alcohol or drug dependence.
- Known or suspected coagulopathy.
- Severe hepatic, cardiac, or renal disease.
- Emergency surgery or repeat surgery.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Erector Spinae Plane Block
Participants will receive an ultrasound-guided bilateral erector spinae plane block at the L1 vertebral level in the postoperative recovery unit. On each side, 20 mL of 0.25% bupivacaine will be injected into the plane between the erector spinae muscle and the transverse process. Participants will also receive standardized perioperative multimodal analgesia and rescue analgesia as needed. |
Ultrasound-guided bilateral erector spinae plane block performed at the L1 vertebral level in the postoperative recovery unit. Following confirmation of needle placement and negative aspiration, 20 mL of 0.25% bupivacaine without adjuvants will be injected between the erector spinae muscle and the transverse process on each side. |
|
Experimental: Deep Erector Spinae Plane Block
Participants will receive an ultrasound-guided bilateral deep erector spinae plane block at the L1 vertebral level in the postoperative recovery unit. On each side, 20 mL of 0.25% bupivacaine will be injected into the plane between the erector spinae and psoas muscles, deep to the transverse process. Participants will also receive standardized perioperative multimodal analgesia and rescue analgesia as needed. |
Ultrasound-guided bilateral deep erector spinae plane block performed at the L1 vertebral level in the postoperative recovery unit. Following confirmation of needle placement and negative aspiration, 20 mL of 0.25% bupivacaine without adjuvants will be injected into the plane between the erector spinae and psoas muscles, deep to the transverse process, on each side. |
|
No Intervention: Control Group
Participants will receive no nerve block. They will receive the same standardized perioperative multimodal analgesia as the two block groups, with rescue analgesia administered as needed. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain Intensity at Rest at 1 Hour After Block Administration
Time Frame: At 1 hour after block administration or the equivalent reference time in the control group
|
Pain intensity at rest will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable). Higher scores indicate greater pain intensity. Assessment will occur 1 hour after completion of bilateral block administration or the equivalent reference time in the control group. |
At 1 hour after block administration or the equivalent reference time in the control group
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain Intensity During Movement at 1 Hour After Block Administration
Time Frame: At 1 hour after Block Administration
|
Pain intensity during movement will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable). Higher scores indicate greater pain intensity. At 1 hour after block administration or the equivalent reference time in the control group |
At 1 hour after Block Administration
|
|
Pain Intensity at Rest Before and After Block Administration
Time Frame: At 0, 15, and 30 minutes and 6, 18, and 24 hours after surgery
|
Pain intensity during movement will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable), at baseline (before block administration) and at 15 and 30 minutes and 6, 18, and 24 hours after block administration, with corresponding assessments in the control group. Higher scores indicate greater pain intensity. Scores will be compared between groups at each assessment time point. |
At 0, 15, and 30 minutes and 6, 18, and 24 hours after surgery
|
|
Pain Intensity During Movement Before and After Block Administration
Time Frame: At 0, 15, and 30 minutes and 6, 18, and 24 hours after surgery
|
Pain intensity during movement will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable), at baseline (before block administration) and at 15 and 30 minutes and 6, 18, and 24 hours after block administration, with corresponding assessments in the control group. Higher scores indicate greater pain intensity. Scores will be compared between groups at each assessment time point. |
At 0, 15, and 30 minutes and 6, 18, and 24 hours after surgery
|
|
Cumulative Rescue Opioid Consumption During the First 24 Hours After Surgery
Time Frame: During the first 24 hours after surgery
|
The total dose of intravenous meperidine administered as rescue analgesia during the first 24 hours after surgery will be recorded in milligrams. Rescue analgesia will be administered at a dose of 0.25 mg/kg when the numerical rating scale (NRS) pain score exceeds 3. Higher consumption indicates a greater requirement for rescue opioid analgesia. |
During the first 24 hours after surgery
|
|
Time to First Rescue Analgesia
Time Frame: From the end of surgery to the first administration of rescue analgesia, up to 24 hours
|
The time from the end of surgery to the first administration of rescue analgesia will be recorded in minutes. Intravenous meperidine at 0.25 mg/kg will be administered when the numerical rating scale (NRS) pain score exceeds 3. Participants who do not receive rescue analgesia during the first 24 hours will be censored at 24 hours. |
From the end of surgery to the first administration of rescue analgesia, up to 24 hours
|
|
Postoperative Nausea and Vomiting Severity
Time Frame: During the first 24 hours after surgery
|
Postoperative nausea and vomiting will be assessed using a five-point scale: 0 = none, 1 = mild nausea, 2 = moderate nausea, 3 = one episode of vomiting, and 4 = more than one episode of vomiting. Higher scores indicate greater severity. |
During the first 24 hours after surgery
|
|
Quality of Recovery at 24 Hours After Surgery
Time Frame: Preoperatively and at 24 hours after surgery
|
Quality of recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire. The questionnaire contains 15 items, with a total score ranging from 0 to 150. Higher scores indicate better quality of recovery. The questionnaire will be administered preoperatively and at 24 hours after surgery. |
Preoperatively and at 24 hours after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Hande Gurbuz, Prof, MD, PhD, University of Health Sciences, Bursa School of Medicine, Bursa City Hospital
Publications and helpful links
General Publications
- Baran O. Quadratus lumborum and erector spinae plane blocks are effective for analgesia in laparoscopic hysterectomy: a randomized controlled trial. Eur Rev Med Pharmacol Sci. 2023 Dec;27(23):11323-11333. doi: 10.26355/eurrev_202312_34571.
- Kilicaslan A, Ciftci B, Aycan IO, Arici AG, Kilic G, Cakin H, Yilmaz R, Alver S, Temel H, Sindel M. Lumbar erector spinae plane block: which side of the fascia? The role of injection depth and volume in a cadaveric model. Pain Med. 2026 May 1;27(5):610-612. doi: 10.1093/pm/pnaf171. No abstract available.
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 26-AKD-261
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
There is currently no plan to share individual participant data with other researchers.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.